Objective: The objective is to study the fluctuation pattern of blood glucose spectrum in patients with end-stage diabetic nephropathy (ESDN) receiving hemodialysis (HD) and peritoneal dialysis (PD), respectively, and to compare the influences of these 2 dialysis methods on glycometabolism. Methods: Sixty-four dialysis patients with ESDN were recruited, including 35 HD patients and 29 PD patients. The 24-h blood glucose on dialysis days of the 2 groups was monitored by the continuous glucose monitoring system, and the relevant glycometabolism indexes were recorded and compared. Results: The control of blood glucose in both groups was not satisfactory. At the same blood glucose level, the dosage of exogenous insulin needed by patients in the PD group was larger than that in the HD group (p < 0.05). However, the fluctuation of blood glucose and consequently the incidence of hyperglycemia and hypoglycemia in HD group were greater than that in PD group (p < 0.05). The patients’ blood glucose levels decreased progressively during the course of HD. The mean blood glucose (MBG) values estimated by glycosylated hemoglobin (HbA1c) in both groups were lower than the actual measured blood glucose values (p < 0.05). Preliminary correlation analysis showed that the deviation of the MBG values estimated by HbA1c was positively correlated with the degree of anemia. Conclusion: HD patients have larger glycemic variability as compared with PD patients, while PD patients have overall increased blood glucose levels. Hypoglycemic programs should be made according to the corresponding changes in blood glucose. The HbA1c value of dialysis patients has a large deviation, so it is necessary to explore its influencing factors and develop more accurate blood glucose assessment indicators.

1.
Zhang
L
,
Long
J
,
Jiang
W
,
Shi
Y
,
He
X
,
Zhou
Z
, et al.
Trends in chronic kidney disease in China
.
N Engl J Med
.
2016 Sep
;
375
(
9
):
905
6
. .
2.
Williams
ME
,
Garg
R
,
Wang
W
,
Lacson
R
,
Maddux
F
,
Lacson
E
 Jr
.
High hemoglobin A1c levels and glycemic variability increase risk of severe hypoglycemia in diabetic hemodialysis patients
.
Hemodial Int
.
2014 Apr
;
18
(
2
):
423
32
. .
3.
Wang
IK
,
Lin
CL
,
Chen
HC
,
Lin
SY
,
Chang
CT
,
Yen
TH
, et al.
Risk of new-onset diabetes in end-stage renal disease patients undergoing dialysis: analysis from registry data of Taiwan
.
Nephrol Dial Transplant
.
2018 Apr
;
33
(
4
):
670
5
. .
4.
Bruen
D
,
Delaney
C
,
Florea
L
,
Diamond
D
.
Glucose sensing for diabetes monitoring: recent developments
.
Sensors Basal
.
2017 Aug 12
;
17
(
8
):
1866
.
5.
KDOQI, National Kidney Foundation
.
KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease
.
Am J Kidney Dis
.
2007
;
49
(
2 Suppl 2
):
S12
154
. .
6.
Lu
QG
,
Tong
NW
.
Interpretation of Chinese society of endocrinology consensus statement on hyperglycemia management target in adult inpatients in China
.
J Diabetes
.
2013 Dec
;
5
(
4
):
416
20
.
7.
Service
FJ
,
Molnar
GD
,
Rosevear
JW
,
Ackerman
E
,
Gatewood
LC
,
Taylor
WF
.
Mean amplitude of glycemic excursions, a measure of diabetic instability
.
Diabetes
.
1970 Sep
;
19
(
9
):
644
55
. .
8.
Zhou
J
,
Mo
Y
,
Li
H
,
Ran
X
,
Yang
W
,
Li
Q
, et al.
Relationship between HbA1c and continuous glucose monitoring in Chinese population: a multicenter study
.
PLoS One
.
2013 Dec
;
8
(
12
):
e83827
.
9.
Zhou
J
,
Li
H
,
Ran
X
,
Yang
W
,
Li
Q
,
Peng
Y
, et al.
Establishment of normal reference ranges for glycemic variability in Chinese subjects using continuous glucose monitoring
.
Med Sci Monit
.
2011 Jan
;
17
(
1
):
CR9
13
.
10.
Xue
C
,
Gu
YY
,
Cui
CJ
,
Zhou
CC
,
Wang
XD
,
Ruan
MN
, et al.
New-onset glucose disorder in peritoneal dialysis patients:a meta-analysis and systematic review
.
Nephol Dial Transplant
.
2019
;
35
(
8
):
1412
9
.
11.
Prázný
M
,
Soupal
J
.
[Glycemic variability and continuous monitoring of glycemia]
.
Vnitr Lek
.
2014 Sep
;
60
(
9
):
757
63
.
12.
Williams
ME
,
Garg
R
.
Glycemic management in ESRD and earlier stages of CKD
.
Am J Kidney Dis
.
2014 Feb
;
63
(
2 Suppl 2
):
S22
38
. .
13.
Gai
M
,
Merlo
I
,
Dellepiane
S
,
Cantaluppi
V
,
Leonardi
G
,
Fop
F
, et al.
Glycemic pattern in diabetic patients on hemodialysis: continuous glucose monitoring (CGM) analysis
.
Blood Purif
.
2014
;
38
(
1
):
68
73
.
14.
Abe
M
,
Kalantar-Zadeh
K
.
Haemodialysis-induced hypoglycaemia and glycaemic disarrays
.
Nat Rev Nephrol
.
2015 May
;
11
(
5
):
302
13
. .
15.
Sayed
M
,
Adnan
F
,
Majeed
M
.
Is HbA1C a true marker of glycaemic control in diabetic patients on haemodialysis?
J Ayub Med Coll Abbottabad
.
2019 Jan–Mar
;
31
(
1
):
46
50
.
16.
Sacks
DB
,
John
WG
.
Interpretation of hemoglobin A1c values
.
JAMA
.
2014 Jun
;
311
(
22
):
2271
2
. .
17.
Expert group on diagnosis and treatment of renal anemia, Nephrology Branch of Chinese Medical Association
.
Chinese experts’ consensus on diagnosis and treatment of renal anemia (2018 revised)
.
Chin J Nephrol
.
2018 Nov
;
34
(
11
):
860
6
.
18.
Rasche
FM
,
Ebert
T
,
Beckmann
J
,
Busch
V
,
Barinka
F
,
Rasche
WG
, et al.
Influence of erythropoiesis-stimulating agents on HbA1c and fructosamine in patients with haemodialysis
.
Exp Clin Endocrinol Diabetes
.
2017 Jun
;
125
(
6
):
384
91
. .
19.
Zendjabil
M
.
Glycated albumin
.
Clin Chim Acta
.
2020 Mar
;
502
:
240
4
. .
20.
Lee
SY
,
Chen
YC
,
Tsai
IC
,
Yen
CJ
,
Chueh
SN
,
Chuang
HF
, et al.
Glycosylated hemoglobin and albumin-corrected fructosamine are good indicators for glycemic control in peritoneal dialysis patients
.
PLoS One
.
2013
;
8
(
3
):
e57762
. .
21.
Isshiki
K
,
Nishio
T
,
Isono
M
,
Makiishi
T
,
Shikano
T
,
Tomita
K
, et al.
Glycated albumin predicts the risk of mortality in type 2 diabetic patients on hemodialysis: evaluation of a target level for improving survival
.
Ther Apher Dial
.
2014 Oct
;
18
(
5
):
434
42
. .
22.
Zelnick
LR
,
Batacchi
ZO
,
Ahmad
I
,
Dighe
A
,
Little
RR
,
Rrence
DL
, et al.
Continuous glucose monitoring and use of alternative markers to assess glycemia in chronic kidney disease
.
Diabetes Care
.
2020 Oct
;
43
(
10
):
2379
87
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.